The primary objective of this study is to evaluate the safety and efficacy of Omiganan (CLS001) topical gel compared to vehicle topical gel applied once daily for 12 weeks in female subjects with moderate to severe inflammatory acne vulgaris.

Inclusion Criteria:

• Non-pregnant female subjects ≥ 12 years of age with facial acne vulgaris
• Subjects with an Investigator's Global Assessment (IGA) of Inflammatory Lesions of Acne Vulgaris of Moderate (3) or Severe (4) at Baseline.
• Subjects with ≥ 30 facial inflammatory lesions

Exclusion Criteria:

• Subjects with < 10 or > 75 facial non-inflammatory lesions
• Subjects with > 3 facial nodular or cystic lesions at Baseline
• Standard exclusion criteria